WuXi Biologics and Fresenius strike major biosimilar partnership

· Health · China · Germany

WuXi Biologics and German drugmaker Fresenius have reached one of the largest biosimilar deals to date, Endpoints News reports. The agreement comes ahead of what some in the industry call an upcoming "golden decade" for biosimilar products, as more brand-name biologics lose exclusivity. The report does not specify financial terms or which products the partnership covers. WuXi Biologics is a major contract development and manufacturing organization, while Fresenius brings a European generic and biosimilar business. Partnering manufacturing capacity with a commercial distributor is a common way to scale biosimilar supply across markets. The deal signals that manufacturers are positioning early for the wave of patent expirations expected to open large new biosimilar markets.

Why it matters：Biosimilar supply is becoming a manufacturing and distribution race, and pairing CDMO capacity with a European commercial partner positions both firms for the patent-expiry wave reshaping drug spending.

Key points

  • The deal is described as one of the largest biosimilar agreements to date.
  • It precedes an expected "golden decade" for biosimilars as more biologics lose exclusivity.

Sources (original reporting)

More stories from this day